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The success of medical interventions for patients with diseases that require
consistent adherence to a medical regimen is largely contingent upon the patient’s
ability to consistently follow medical recommendations. Medical regimen adherence
significantly influences the patient’s health and impacts the health care providers’
ability to treat any disease or medical problem. Adherence levels are particularly low
in the pediatric population among young patients with diabetes and cystic fibrosis.
Researchers and clinicians hypothesize that levels of adherence are particularly low
during adolescence (ages 11-15) because this may be the period in which primary
responsibility for daily adherence is transferred from the parent to the child patient
(Miller & Drotar, 2003).
The current investigation is designed to provide a systematic analysis of how
age, perceived responsibility for treatment procedures, levels of parental involvement
in treatment procedures, and conflict are related to treatment adherence in diabetic
and cystic fibrosis populations. Data were collected from 64 diabetic parent-child
dyads, and 27 cystic fibrosis parent-child dyads (children ages 7-18).

Several

significant results are reported from the current data set. First, internal consistency

and test-retest psychometric data are provided for previously established adherence
assessment instruments including the Cystic Fibrosis Family Responsibility
Questionnaire (CFFRQ), the Diabetes Family Responsibility Questionnaire (DFRQ),
the Conflict Subscale of the Diabetes Responsibility and Conflict Scale (Conflict
Subscale-DRCS) and the Self-Care Inventory (SCI).

In addition, the internal

consistency and test-retests reliability results are reported for the newly developed
versions of the Modified Conflict Subscale for the Cystic Fibrosis Responsibility and
Conflict Scale (Conflict Subscale-CFRCS) and the Modified Self-Care InventoryCystic Fibrosis (SCI-CF).
Results of this investigation suggest that agreement between parents and their
children regarding who is primarily responsible for completing treatment tasks on a
daily basis may be the most significant predictor of adherence levels within both the
diabetic and cystic fibrosis populations. These findings are discussed in relation to
the impact they may have on providing medical recommendations for similar patients
in the medical setting, and how these results compare to the findings in similar studies
that have been conducted in the area of pediatric medical regimen treatment
adherence.
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CHAPTER 1

INTRODUCTION

Treatment adherence to medical regimens significantly affects the overall
delivery of health care services by altering levels of intervention success and altering
patient health. Treatment adherence is defined as, “the extent to which a person’s
behaviors (e.g., medication administration, following diets) coincide with medical or
health advice” (Haynes, 1979, p. 2). Nonadherence can negatively impact patient
health and complicate clinician decision-making, increase healthcare costs, and
distort treatment efficacy research (Rapoff, 2001).

Research on adherence is

considered critical in the psychological and medical communities because
understanding how to increase adherence could lead to increases in the overall quality
of healthcare service and patient quality of life (Allen & Warzak, 2000).
Many medical and psychological investigations have examined factors that
influence adherence levels and techniques for increasing patient's compliance with
recommended treatments (Rapoff, 2001).

These investigations have all faced

challenging measurement issues such as forced reliance on patient report that are
inherent in the study of treatment adherence. Patient or parent reports are often
influenced by factors such as social desirability and distorted memory of the past
(McDonald, Garg, & Haynes, 2002). Clinicians’ personal judgment and predictions
of adherence have also proven an inaccurate measure of treatment adherence
(Stephenson, Rowe, & Haynes, 1993) leading most researchers to rely on
1

patient/parent report in spite of the aforementioned drawbacks. The studies described
in this literature review are based on measures of patient/parent report unless
otherwise indicated.
Adherence to medical regimens is surprisingly low and is typically not
significantly affected by clinician instruction.

Adherence rates for short-term

treatment regimens that last 2 weeks or less are approximately 50% and are
significantly lower for more demanding treatment regimens that require lifetime
adherence on a a daily basis (McDonald et al., 2002). Furthermore, research suggests
that clinician instruction does not significantly affect the long-term behavior or levels
of treatment adherence for individuals who suffer from chronic disease (McDonald et
al., 2002). Poor adherence to long-term treatment regimens is particularly concerning
because long-term regimens are associated with chronic diseases that greatly impact
lifelong health, viability and livelihood of patients.
Treatment of chronic disease presents challenges to families and physicians,
particularly when the patient is a child or adolescent. Chronic pediatric diseases such
as cystic fibrosis (CF) and insulin dependent diabetes mellitus (IDDM) often have
low and variable rates of adherence, with estimates for CF regimen adherence ranging
from 16% to 90% and estimates for IDDM ranging from 10% to 80% (Anderson, Ho,
Brackett, Finkeistein, & Laffel, 1997; Jacobson, et al., 1990; Lask, 1994). Regimens
for these diseases include multiple daily treatment components targeting overall
health of the patient (Bartholomew, Parcel, Seilheimer & Czyzewski, 1993; Eaton,
Larson, Mengel, Campbell, Mengel, & Montague, 1992). Management of these
diseases requires the family and the child to regularly administer medication, alter
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their diet, and make various other lifestyle changes (Bartholomew et al., 1993; Eaton
et al., 1992). These demands require the family to become experts on the disease
during the course of monitoring and improving the child's condition. After acquiring
knowledge about the disease and treatment, the family must commit to
implementation, alter their lifestyle, and deal with the stress associated with these
changes (Kyngas, Kroll, & Duffy, 2000). For the medical professional, the greatest
challenge is determining whether the patient's health status is related to noncompliance, non-responsiveness to appropriately delivered medical intervention, or
the general, inevitable, deterioration of the health of the patient.
Several factors influence the adherence of individuals with chronic disease
regimens: (a) general demographic factors, (b) characteristics of the specific disease,
(c) specific aspects of the regimen itself, and (d) variables associated with the patient
and family. The following sections review the primary variables investigated for
individuals with CF and IDDM. General demographic factors such as family income
and level of education are positively associated with treatment adherence and these
correlations remain relatively stable throughout the course of the patients’ disease
(Johnson, Kelly, Henretta, Cuningham, Tomer, & Silverstein, 1992; Kovacs, Kass,
Schnell, Goldston, & Marsh, 1989). In addition to demographic factors, three groups
of variables influence treatment adherence for pediatric CF and IDDM regimens
(LeBlanc & Goldsmith, 2003; Lemanek, Kamps & Chung, 2001). The first category
includes the characteristics of the specific disease (e.g., severity, age of onset, impact
on cognitive functioning), which influence the probability that patients will comply
with treatment regimens. The second category includes specific aspects of regimen
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itself (e.g., procedural complexity, frequency of implementation, efficacy, and side
effects). The third category refers to variables associated with the patient and their
family such as level of family dysfunction and related skills (e.g., poor
communication, high levels of stress, lack of problem solving skills, coping
strategies). The following sections will provide a brief general overview of the first
two categories, disease characteristics, and intervention regimens for each disease.
The third category will be examined in greater detail and will be the focus of the
proposed investigation.
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CHAPTER 2

LITERATURE REVIEW

IDDM Disease Characteristics
IDDM results from a failure of the pancreas to produce or effectively regulate
the release of insulin. This failure often leads to medical complications such as
vascular disease, blindness, renal impairment, and neuropathology (Drash, 1978).
Researchers believe that the malfunction of insulin producing cells within the
pancreas is related to the autoimmune process; however, the specific mechanism of
change responsible for this breakdown has not yet been identified (Thai & Eisenbarth,
1993).
The current literature does not provide a clear picture of the impact of IDDM
on the cognitive functioning of patients or how any impaired functioning might
influence an individual’s adherence to the recommended treatment regimen. There
appears to be consensus within the literature that IDDM may be associated with longterm degenerative changes in the central nervous system (Prescott, Richardson, &
Gillespie, 1990; Ehrlich, 1999). However, there is disagreement as to whether or not
this neurological decay presents individuals with any significant performance
difficulties either immediately or over time.

Some research suggests that

hypoglycemia has little impact on patient’s cognitive functioning or academic
performance (Hough, 1995). Findings on the impact of hypoglycemia on cognitive
functioning are equivocal.

The researchers found no statistically significant
5

difference between the cognitive performance of individuals who suffer from IDDM
and those who do not (Ehrlich, 1999; Prescott et al., 1990). Other literature has
demonstrated delays on some developmental tasks when comparing adolescents who
suffer from IDDM to their healthy peers (Rovet, Ehrlich, & Czuchta, 1990).

IDDM Regimen Characteristics
IDDM treatment recommendations require potentially dramatic shifts in
lifestyle. Treatments designed for IDDM include procedures to normalize serum
glucose by providing exogenous insulin paired with altered dietary practices in order
to regulate intake of simple sugars and saturated fats (Greydanus, Draznin, & Hare,
1997). The first required activity is the administration of some form of insulin and
monitoring of blood glucose. Some diabetics inject insulin while others take pills that
help their bodies produce more insulin and/or use produced insulin more effectively.
Individuals with IDDM also monitor their blood glucose levels daily to evaluate how
well their regimen is keeping blood sugars in a normal range and to indicate when
insulin administration is required to bring blood sugar into the normal range
(Greydanus et al., 1997). The second group of critical activities includes a healthy
diet and consistent exercise. Dietary changes include increased starch intake (e.g.,
breads, cereals, and nuts) to clean the lower gastrointestinal tract, increased fruit and
vegetable intake to reduce the absorption of glucose from the intestines, and
decreased consumption of sugars to help stabilize blood glucose levels. A consistent
exercise regimen can assist the body in more productively and efficiently managing
insulin to convert glucose into energy for cells (Greydanus et al., 1997).

6

The daily management of IDDM requires that the pediatric patient become
partially responsible for daily monitoring of glucose, administration of insulin, and
dietary control and exercise activities.

Younger children typically follow adult

instruction during the implementation of each of these components while
preadolescents and adolescents may assume more independence for treatment
implementation. Implementation of treatment components may prove particularly
difficult for children aged 11 to 15 who are not developmentally capable (i.e.,
maturity and cognitive abilities) of following through with aspects of treatment on a
consistent, daily, basis but are constantly striving from independence from their
parents in all aspects of their lives (Davis, Delamater, Shaw, La Greca, Edison, PerezRodriguez, & Nemery, 2001; Greydanus et al., 1997). Additionally, the most
distressing negative effects of non-adherence in IDDM are usually cumulative and
delayed (e.g., renal failure, heart failure, growth failure) rather than immediately
evident while immediate effects (e.g., fatigue, weight loss, frequent urination) are
often less aversive than regimen compliance (Greydanus et al., 1997; Silverstein,
1994).

CF Disease Characteristics
CF is a chronic illness hypothesized to result from genetic variance on
chromosome 7 (Wilmott & Fielder, 1994). This variance appears responsible for the
development of symptoms such as excessive secretions in the lungs, pancreas, small
bowel, liver and reproductive glands.

In addition to excessive secretions, an

excessive amount of salt and water are lost through sweat glands during exercise
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(Bartholomew & Schwartz, 1991).

These two factors produce complications

including lung damage and high levels of lung mucus and infections. Pulmonary
complications of this nature lead to impaired functioning, respiratory failure, and
ultimate fatality for 90% of CF sufferers (Greydanus & Homnick, 1997). While some
individuals avoid symptoms of CF until the third or fourth decade of life, most
patients will experience gastrointestinal and pulmonary complications from the onset
of the disease (Greydanus & Homnick, 1997). If a physician identifies CF soon after
birth, the family becomes responsible for implementing the treatment regimen and
responsibilities gradually shift to the patient as they mature (Sherbourne, Hays,
Ordway, DiMatteo, & Kravitz, 1992). Treatment adherence in CF often becomes a
practice incorporated into daily life from birth.
Though it is rare for patients that suffer from CF to live a normal life span, life
expectancy does increase with regimen adherence (Jackson, 1989).

Improved

treatment methodologies for CF have increased the average life expectancy
dramatically over the past 30 years. Life expectancy rates vary from country to
country, but the average life expectancy increased from approximately seven years in
the 1960's to approximately 17 years in the 1970’s and to almost 35 years in 1995
(NIH, 1997).

It is estimated that children with CF born in 1990 will live

approximately 40 years (Elborn, Shale, & Britton, 1992).

The perception of

unavoidable fatality appears to significantly impact compliance with treatment
recommendations within the adolescent population (Lask, 1994) as high levels of
optimism are associated with engagement in the various complicated aspects of the
CF management routine. As treatment methodologies improve, adolescents may look
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forward to a life that extends well into the 30’s, however, the reality of a truncated
lifespan will continue to challenge patients and their families as they try to remain
optimistic.
CF does not appear to be associated with any cognitive impairment that might
influence levels of treatment adherence; however there is evidence to suggest that
adolescents who are diagnosed with this disease might be impacted in regards to
psychosocial development. Research suggests that individuals, especially females,
who suffer from CF might be slightly delayed in regards to self-esteem and overall
adjustment compared with individual who do not suffer from CF (Sawyer, Rosier,
Phelan, & Bowes, 1999). Furthermore, other research suggests that individuals who
suffer from CF have a lower level of peer interaction than individuals without chronic
disease (Meijer, Sinnema, Bijstra, Mellenbergh, & Wolters, 2000). Lower levels of
peer interaction might lead to a restricted social skills set due to limited opportunities
to develop and practice them. These factors suggest that decisions about treatment
responsibility should be based on developmental maturity, rather than on age, because
of the potential for slightly delayed psychosocial development.

CF Regimen Characteristics
Treatment regimens for CF include complicated procedures requiring
extensive resources and knowledge to execute interventions (Greydanus & Homnick,
1997). These regimens include daily physiotherapy (e.g., back pounding to loosen
mucus secretion followed by suctioning) and/or exercise to reduce the risk of lung
infection (Greydanus & Homnick, 1997).
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An antibiotic regimen is often

implemented to reduce the chances of lung infection. A high calorie diet may also be
recommended to reduce the risk of rapid weight loss and to stimulate digestive
enzymes that assist in absorption of nutrients that are otherwise prematurely secreted
(Willis, Miller, & Wyn, 2001).
Treatment regimens for IDDM and CF entail some level of complexity and
require daily adherence making them tedious and time consuming (Kyngas et al.,
2000). Research suggests that the level of procedural complexity does not necessarily
prevent good adherence, but the constant attention and consistency required strongly
influences adherence. Current research suggests that treatment adherence decreases
as the responsibility for treatment implementation and monitoring passes from the
parent to the child (Eaton et al., 1992), however, it is not clear why this drop occurs.
The decrease in adherence may be due to the loss of a structure for reinforcement and
support provided by the family system for younger children (Eaton et al., 1992), or
might occur if the responsibility transition precedes the developmental readiness of
the adolescent.

Additionally, several questions remain unanswered about the

psychosocial factors that might impact treatment adherence for adolescents becoming
more autonomous in their health care. The following sections provide a literature
review of selected articles that investigate these psychosocial factors and their
relationship to treatment adherence within the pediatric population.

Psychosocial Factors that Impact Adherence
Research indicates that three sets of interconnected individual and family
functioning variables can impact adherence. The age and developmental functioning

10

of the child patient, the level of parental involvement in the intervention, and the
overall level of family conflict can each affect levels of treatment adherence. These
three variables also interact to produce a complex picture of the impact of
psychosocial variables on treatment adherence. The following sections will review
the impact of these three factors on adherence for IDDM and CF regimens.
Age and Developmental Level
There is a great deal of interest in the relationship between age and treatment
adherence for both IDDM and CF (Davis et al., 2001; Drotar & Ivers, 1994; Johnson
et al., 1992; Ricker, Delamater, & Hsu, 1998; Rubin, Young-Hyman, & Peyrot,
1989). In much of the literature regarding treatment adherence, chronological age is
measured and examined as a predictor of the ability of a patient to complete tasks
independently.

However, the reader should note that chronological age is not

necessarily equivalent to developmental level in terms of cognitive functioning, level
of psychosocial development, or maturity. It is currently unclear which psychosocial
characteristics are critically related to age and its’ impact on treatment adherence.
However, in spite of the limitations of using chronological age rather than a measure
of developmental level, age is a commonly measured variable in psychological and
medical literatures. Many investigations have attempted to determine whether age is
strongly correlated with treatment adherence and to identify the ages that might be
associated with higher and lower levels of treatment (Davis et al., 2001; Drotars &
Ivers, 1994; Johnson et al., 1992; Ricker et al., 1998; Rubin et al., 1989).
Developmental theories are then often used to interpret the potential factors
contributing to success or difficulties with compliance at a given age.
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Several studies support the finding that age is associated with levels of
treatment adherence. Johnson et al. (1992) assessed the relationship between age and
treatment regimen adherence in 193 youngsters who suffered from IDDM. This twoyear longitudinal study used structural equation modeling to examine the impact of
patient age and disease duration on several measures of treatment adherence. Results
of the models created during this investigation suggested that age was a predictor of
levels of treatment adherence and metabolic control. The models suggested that older
youngsters were less successful with adherence and with achieving metabolic control.
Additionally, regimen aspects of diet, frequency of glucose testing, and frequency of
injections were most closely associated with greater metabolic control suggesting that
some regimen components may be more critical than others.
Ricker et al. (1998) also assessed the relationship between levels of treatment
adherence and age in 50 children. Researchers conducted phone interviews on three
separate occasions to obtain information regarding treatment adherence and
correlated the results with survey responses measuring health locus of control, selfcompetency, and age using a hierarchical multiple regression analysis.

They

suggested that younger age is correlated with higher levels of regimen adherence
among children who suffer from CF.
Finally, Jacobson et al. (1990) conducted a 4-year longitudinal study of
treatment adherence in individuals with IDDM. Factors associated with higher levels
of treatment adherence were child “ego defense level,” level of adjustment to the
disorder, and age. Patient’s level of diet adherence, insulin adjustment, and metabolic
monitoring were higher for preadolescents (age 9-12) than for adolescents (13-16)
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suggesting that younger children were more compliant to treatment recommendations.
However, this study did not include an investigation into the level of involvement of
parents in the treatment process, which has been shown to affect adherence.
Parental Involvement
Drotar & Ivers (1994) compared the relations between age and level of child
treatment responsibility in pediatric populations with CF and IDDM. Twenty-six
individuals and their parents completed the Diabetes Family Responsibility
Questionnaire and the Cystic Fibrosis Family Responsibility Questionnaire to indicate
who was responsible for treatment implementation. No measures of actual adherence
were collected and no examination of the relation between parental level of
involvement and child age were conducted. Their results suggest that older children
may perceive themselves as more responsible for implementing the treatment regimen
independently.

However, parents reported that their involvement in treatment

components did not change significantly as children grew older (11-14 years)
suggesting a discrepancy between child and parent perception of responsibilities.
Children may inaccurately perceive themselves as achieving independence when
levels of parental involvement may continue at a relatively stable level throughout
adolescent development.
In another investigation of the association between levels of parental
involvement and treatment adherence, Wiebe et al. (2005) suggested that parents
levels of involvement in treatment was a predictor of levels of treatment adherence
measured though Glycosylated Hemoglobin. A sample of 127 children, ages 10 – 15
years, diagnosed with IDDM completed surveys assessing parental involvement
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among other factors that might influence treatment adherence. According to the
children surveyed in this investigation, there was a strong relationship between higher
reported levels of parental involvement and treatment adherence. These results also
suggested that children report a strong association between lower levels of parental
involvement and increased age of the child. Taken together, these results suggest that
parents are less involved in treatment as children age, and that levels of treatment
adherence are lower as children grow older.
Though the results of the Wiebe et al. (2005) investigation did not take into
account parent report of their level of involvement in treatment, the Drotar and Ivers
(1994) investigation suggested discrepancies in the report between parent and their
children regarding levels of parental involvement in treatment resulted in lower levels
of treatment adherence.

Conflicting perceptions of child independence may

contribute to the third relevant psychosocial variable, increased levels of conflict
between parents and their offspring that emerge as children enter late childhood and
early adolescence.
Increased Family Conflict
While parental knowledge and involvement is instrumental in increasing
pediatric treatment adherence (Anderson, Auslander, Jung, Miller, & Santiago, 1990;
Anderson et al., 1997; Kyngas et al., 2000), older children are generally less receptive
to instruction from their parents, which may produce greater levels of conflict within
the family (Graetz, Shute, & Sawyer, 2000; Schafer, McCaul, & Glasgow, 1986). If
family conflict increases, adherence is usually impacted negatively (Martin, MillerJohnson, Kizmann, & Emery, 1998; Miller-Johnson, Emery, Marvin, Clarke,
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Lovinger, & Martin, 1994). If the family system, however, is successful in increasing
family involvement and providing an emotional support system without increased
conflict, then increased family involvement has been demonstrated to have a positive
impact on levels of treatment adherence (Martin et al., 1998).
In a recent study examining family factors associated with treatment
adherence in IDDM, Miller and Drotar (2003) investigated the relation between levels
of conflict and child/parent perceptions of decision making in regards to treatment.
Eighty-two mother-child dyads were issued a series of questionnaires designed to
assess perceptions of child autonomy in treatment decision-making, the level of
treatment adherence, and the level of parent-child conflict. Results suggested an
association between discrepant reports of the child’s level of autonomy in decisionmaking and levels of parent-child conflict. Specifically, when children reported
greater levels of autonomy in decision-making than mothers acknowledged, there was
a greater level of reported conflict. Results also suggested that there was a significant
negative correlation between mothers’ report of conflict and mothers’ report of
treatment adherence. That is, from the perspective of the mothers surveyed, higher
levels of diabetes-related conflict were associated with lower levels of treatment
adherence. Associations between age and autonomy or age and conflict, however,
were not investigated due to the limited participant age range (11 - 17 year olds).
This study was specific to IDDM and did not include individuals with CF, leaving the
question about potential parallels between these two diseases unanswered.
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Summary of Current Findings and Rationale for the Proposed Study
Several studies suggest that psychosocial development associated with age,
levels of parental involvement, and levels of family conflict significantly impact
treatment adherence for children with chronic diseases such as IDDM and CF.
However, several critical questions about these three psychosocial factors still remain.
It is unclear whether increased parental involvement is always associated with levels
of conflict within the family or if it is only problematic for adolescents. Additionally,
it is unclear when parental and child reports of disease management autonomy
become discrepant. Research that compares the impact of these three factors in
families of children who suffer from IDDM and CF may be useful because unique
aspects of each disease or regimen might influence perceived autonomy or the age at
which reports of perceived autonomy become discrepant.
Clinicians who make recommendations about child and adult responsibility
for regimen implementation are faced with conflicting findings. Older children are
less likely to adhere to treatment regimens (Anderson et al., 1997) and parental
involvement decreases with age. Increased parental involvement for older children
often produces increased family conflict, which is in turn associated with poor
adherence. Clinicians may be reluctant to recommend that parents become more
involved knowing that increased parental involvement may lead to increased conflict
and a decrease in treatment adherence. However, without their involvement many
adolescents may lose ground in their health status. Information regarding when and
which treatment responsibilities should be delegated to the parent and the child could
be useful for clinicians when attempting to reduce conflict and increase adherence.
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Researchers hypothesize that by explicitly assigning specific treatment tasks, medical
professionals might eliminate the discrepancy between perceptions of autonomy,
which may reduce conflict and increase treatment adherence (Anderson et al., 1997).
Further research is needed to clarify the age at which children’s level of
adherence begins to decrease and the level of parental involvement that is useful in
increasing adherence without increasing conflict. Currently, there are reliable tools
for assessing these factors and normative data for these factors with children with
IDDM. However, tools for children with CF either have not yet been developed or
have less available psychometric information. Development of additional tools and
norms and further evaluation of psychometric properties of existing tools for
variables such as conflict within the family and levels of treatment adherence are
needed.

Data of this nature could contribute to the development of guidelines

regarding recommendations for treatment responsibilities when working with the CF
population. Furthermore, clear research findings regarding age and appropriate level
of treatment autonomy could lead to clinical guidelines for transfer of treatment
responsibilities from the family as a whole to adolescents who suffer from both
IDDM and CF. Recommendations of this nature could lead to lower levels of conflict
within the family and possibly increase the probability of treatment adherence.
Additional research is also needed to examine potential parallels or differences in CF
and IDDM populations.
The current investigation is designed to provide a systematic analysis of how
age, perceived responsibility for treatment procedures, level of parental involvement
in treatment responsibilities and conflict are related to treatment adherence for both
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CF and IDDM patients. The current investigation has three specific goals. First, we
will provide psychometric data including further reliability data for the Cystic
Fibrosis Family Responsibility Questionnaire (CFRCS), the Diabetes Family
Responsibility

Questionnaire

(DRCS),

Conflict

Subscale

of

the

Diabetes

Responsibility and Conflict Scale (Conflict Subscale – DRCS) and the Self-Care
Inventory (SCI). In addition, we will assess the internal consistency of the newly
developed versions of the Modified Conflict Subscale of the Cystic Fibrosis
Responsibility and Conflict Scale (Conflict Subscale – CFFCS) and the Modified
Self-Care Inventory – Cystic Fibrosis (SCI – CF). Second, we will attempt to clarify
the relationship between age, perceived responsibility for treatment procedures, level
of family conflict and treatment adherence for children with IDDM and CF. Finally,
we will attempt to determine the combined level of prediction these variables may
have in regards to levels of treatment adherence for each disease.
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CHAPTER 3

METHOD

Participants
Participants were recruited from three separate community outpatient medical
clinics that also serve as research training facilities for large university medical
schools. These clinics were all dedicated to the long term care of children who suffer
from IDDM and CF.

Patients were seen in these clinics on a semi-regular basis;

approximately every two months for children with CF and approximately every three
to six months for children who suffer from IDDM. All participants attended a
minimum number of five scheduled appointments to ensure that they had been
followed by outpatient clinic for approximately one year. This level of attendance
also ensured that the family received instructions on the treatment regimen they were
recommended to follow. Clinic staff reviewed the records of potential participants to
determine their eligibility for the study.
Data were collected from 64 parent-child dyads with a child (ages 7 to 18)
diagnosed with IDDM and 27 parent-child dyads (ages 7 to 18) with children
diagnosed with CF. Participant demographics and characteristics are included in
Tables 1 and 2 (IDDM) and Tables 3 and 4 (CF).
The mean Glycohemoglobin levels for IDDM group were 8.88 which is
similar to the average for the clinic in which these data were collected. Children in
the IDDM group primarily came from homes where parents were continuously
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married (n = 49, 76.6%) and most lived with their biological mother and father (n =
47, 73.4%). Almost half of the children surveyed reported that it had been seven
years, or more, since they were diagnosed with IDDM (n = 29, 45.3%). The average
age of children in the IDDM group was 13.89 years (range, 8 – 18).

Table 1
Characteristics of IDDM Child Participants

Characteristic

Value

Gender
Male

32

Female

32

M

13.89

SD

2.77

Range

8 – 18

Age

Glycohemoglobin (HbA1)
M

8.87

SD

1.93

Range

5.20 – 14.50
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Table 2
Demographics of IDDM Child Participants
Demographic

Frequency (Percent)

Duration Since Diagnosis
1 year

4 (6.3 %)

2 years

11 (17.2 %)

3 years

2 (3.1 %)

4 years

9 (14.1 %)

5 years

3 (4.7 %)

6 years

6 (9.4 %)

7 years or more

29 (45.3 %)

Living Status of Child
Lives with Mother and Father

47 (73.4 %)

Live with Mother

6 (9.4 %)

Lives with Father

1 (1.6 %)

Lives with Mother and Stepfather

5 (7.8 %)

Lives with Father and Stepmother

2 (3.1 %)

Other

3 (4.7 %)

Marital Status of Biological Parents
Continuously Married

49 (76.6 %)

History of Separation or Divorce

13 (20.3 %)

One Parent Deceased

2 (3.2 %)
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Table 3
Characteristics of CF Child Participants

Characteristic

Value

Gender
Male

15

Female

12

M

13.70

SD

2.52

Range

8 – 18

Age

In the CF group, almost all children had been diagnosed with the disease for
seven years or more (n = 22, 81.5%, range, 1 – 7 or more). Parents were continuously
married for the majority of children who participated (n = 20, 74.1%) and all of the
children who reported that their parents were continuously married, reported that they
lived with their biological parents (n = 20, 74.1%). Children in the CF group were an
average of 13.7 years of age (range, 9 – 18).
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Table 4
Demographics of CF Child Participants
Demographic

Frequency (Percent)

Duration Since Diagnosis
1 year

1 (3.7 %)

2 years

0 (0 %)

3 years

0 (0 %)

4 years

1 (3.7 %)

5 years

1 (3.7 %)

6 years

2 (7.4 %)

7 years or more

22 (81.5 %)

Living Status of Child
Lives with Mother and Father

20 (74.1 %)

Live with Mother

2 (7.4 %)

Lives with Father

1 (3.7 %)

Lives with Mother and Stepfather

2 (7.4 %)

Lives with Father and Stepmother

0 (0 %)

Other

2 (7.4 %)

Marital Status of Biological Parents
Continuously Married

20 (74.1 %)

History of Separation or Divorce

6 (22.2 %)

One Parent Deceased

1 (3.7 %)
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Procedures
Administration of Measures
During their appointment, a medical staff member not involved in the research
project, asked potential participants if they were interested in hearing about the study.
A researcher personally offered to talk with the family about the study and invited
them to participate in the study if they expressed interest. While the family waited for
their appointment, they were approached by a medical professional or researcher with
the informed consent document and letter of invitation to participate in the study.
The presenter then briefly reviewed the letter of invitation for the patient and their
family. At this time, potential participants were also told that they would receive a
$10.00 gift card to Target after they completed all of the surveys.
Patients who signed the informed consent and assent forms were issued
several measures to be completed onsite while waiting for the physician (see
descriptions of measures below): the demographic questionnaire, the DFRQ or the
CFFRQ (depending upon diagnosis), the Conflict Subscale - DRCS, modified
Conflict Subscale – CFRCS, and the SCI or the modified SCI - CF. Parents and
children completed the questionnaires in separate rooms to minimize demand effects
from parental instruction or reactivity due to the presence of the parent or child. If
younger children (i.e., 7-10-year-olds) were unable to read the items contained in the
questionnaires, a researcher read the questions to them. Participants were offered the
opportunity to retake the questionnaire packet for an additional gift card at a later
appointment in order to obtain test-retest reliability on all of the measures in the
questionnaire packets. In the IDDM group, eight participants were willing to return
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to the clinic setting and retake all questionnaires, and in the CF group six participants
were willing to retake the questionnaires.
Measures of Treatment Adherence
Self-Care Inventory (SCI).

The Self-Care Inventory (SCI) measures

treatment adherence in individuals with IDDM over the previous two-week period
(See Appendix A). This measure was selected because it is well established for
assessing reported treatment adherence in children with IDDM (Harris, Greco,
Wysocki, Elder-Danda & White, 1999; Miller & Drotar, 2003). The coefficient alpha
was .51 for parent report and .78 for child report in the current sample. This level of
internal consistency for parental report is significantly lower than previous estimates
(.83 for parent report) but similar to previous estimates for child report (.86) (Greco,
La Greca, Ireland, Wick, Freeman, & Agramonte, 1990).
Modified Self-Care Inventory - CF (SCI - CF). The standard version of the
SCI was modified to assess adherence to the treatment components for CF (See
Appendix B). This modified version was developed with the help of two Pediatric
Pulmonologists who reviewed the original SCI for children with diabetes, and
developed items that asked about adherence to specific components of the CF
treatment regimen. As on the original SCI, 14 items were developed for this modified
version and the items were designed to parallel items from the original SCI in regards
to content and similarity of treatment components. This measure was developed
specifically for this investigation; therefore there was no psychometric data available
prior to this investigation. In this sample the coefficient alpha was .32 for child report
and .95 for parent report. Based on the low internal consistency of the child report on
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the modified SCI - CF, only the parent report served as a measure of treatment
adherence for CF participants.
Glycohemoglobin (HbA1). A measure of Glycohemoglobin was obtained by
drawing blood samples at the time of the visit to determine the patient’s glycemic
control, or levels of treatment adherence. Lower levels of Glycohemoglobin indicate
better glycemic control and suggest higher levels of adherence to the diabetes
treatment regimen.

Total glycolated hemogloblin (HbA1) was measured using

electrophoresis. This measure was compared to parent and child reported adherence
on the SCI to determine the accuracy of parent and child report of adherence on the
SCI.
No comparable physiological measure was available for individuals who
suffer from CF because of the variability of the disease and the progressive
degenerative nature of the disease.

These factors made it difficult to estimate

adherence levels based on physiological measures for individuals with CF. The SCICF (parent report) was therefore used to measure the levels of adherence in
participants with CF.
Measures of Perception of Responsibility
Diabetes Family Responsibility Questionnaire (DFRQ). Individuals who
suffer from IDDM were administered this measure, developed by Drotar and Ivers
(1994), to assess the level of parental involvement in treatment responsibilities (See
Appendix C). The internal consistency of this measure was previously reported at .92
based on Cronbach’s alpha (Drotar & Ivers, 1994). The coefficient alpha in this
sample was .83 for parents and .79 for children. This measure was issued to the child
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and the primary caregiver to determine the level of consistency between the two
reports. Levels of exact agreement were calculated to determine the extent to which
parents and children agreed on who was responsible for completing treatment tasks
on a daily basis.

Discrepancies between parents and their children regarding

treatment responsibilities were assessed using exact agreement between responses on
this measure. For the DFRQ, exact agreement was defined as both the parent and the
child providing the same response as to who they perceive as primarily responsible
for treatment adherence on a given item. Exact agreement between parent and child
report on the DFRQ was calculated by dividing the number of agreements by the
number of agreements plus disagreements and multiplying by 100%. The mean
percentage agreement between parents and children on this measure for the IDDM
group was 56.69% (range, 32.00% – 88.00%).
In addition to measuring the level of agreement between parents and children
regarding treatment responsibilities, this measure was also used to assess the level of
perceived parental involvement in completing the diabetes treatment regimen. The
questionnaire asks parents and children who they perceive as responsible for
treatment adherence. A lower score indicates that the responder perceived a higher
level of parental involvement in completing the various treatment tasks queried
within the DFRQ.
Cystic Fibrosis Family Responsibility Questionnaire (CFFRQ). The level of
reported parental involvement in treatment implementation was assessed using this
measure developed by Drotar and Ivers (1994) for children with CF (See Appendix
D). The internal consistency of this measure was previously reported at .75 based on
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Cronbach’s alpha (Drotar & Ivers, 1994). An evaluation of the internal consistency
in this analysis revealed an alpha of .80 for parents and .85 for children. This
measure was issued to both the child and the primary caregiver in order to determine
if discrepancies existed between the two reports in regards to perceived
responsibilities for completing various aspects of the treatment regimen for diabetes.
Discrepancies between parents and their children regarding treatment responsibilities
were assessed using exact agreement between responses on this measure. For the
CFFRQ, exact agreement was defined as both the parent and the child providing the
same response as to who they perceive as primarily responsible for treatment
adherence on a given item. Exact agreement between parent and child report on the
CFFRQ was calculated by dividing the number of agreements by the number of
agreements plus disagreements and multiplying by 100%. For the CF group, the
mean exact agreement between parents and children regarding treatment
responsibilities on this 18 item instrument was 59.87% (range, 33.33% – 88.89%).
Similarly to the DFRQ, the CFFRQ was also used to assess the level of
perceived parental involvement in completing the CF treatment regimen.

The

questionnaire asks parents and children who they perceive as responsible for
treatment adherence. As with the DFRQ, a lower score indicates that the responder
perceived a higher level of parental involvement in completing the various treatment
tasks queried on CFFRQ.
Measures of Level of Family Conflict
Conflict Subscale of the Diabetes Responsibility and Conflict Scale (Conflict
Subscale – DRCS). The levels of family conflict were assessed using the Conflict
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Subscale of the Diabetes Responsibility and Conflict Scale, which has been used by
both Miller & Drotar (2003) and Rubin et al. (1989) and found to significantly
correlate to the Conflict subscale of the Family Environment Scale (Rubin et al.,
1989).

This measure assesses levels of conflict associated with each typically

recommended treatment component for IDDM and was issued to both the child and
the parent (See Appendices E & F).

Miller and Drotar (2003) calculated the

coefficient alpha of this measure at .85 for parental report and .94 for adolescent
report within their study. This investigation revealed a significantly lower coefficient
alpha of .59 for parent report and .65 for child report.
Conflict Subscale of the Cystic Fibrosis Responsibility and Conflict Scale
(Conflict Subscale – CFFCS). For this investigation, items on the standard version
of the Conflict Subscale of the Cystic Fibrosis Responsibility and Conflict Scale were
modified to assess treatment related conflict for individuals and families with CF (See
Appendices G & H). The CF conflict scale was developed with the help of two
Pediatric Pulmonologists who had reviewed the original IDDM conflict measure.
The Pulmonologists and primary investigator collaboratively developed items that
paralleled items from the IDDM conflict measure, and that reflected all aspect of the
CF treatment regimen. This instrument measured levels of conflict associated with
each typically recommended treatment component for CF. Assessment of the internal
consistency for this new measure revealed a coefficient alpha of .71 for parents and
.52 for children.
Conflict Behavior Questionnaire (CBQ).

This instrument measures the

overall level of conflict and the negative communication in parent-child relations
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outside the realm of diabetes and diabetes treatment (See Appendix I). The 73 item
version has been shown to have good internal consistency (a = .90; Prinz et al., 1979)
and reasonable test-retest reliability (correlations range from .37 to .85), as well as
construct validity (Robin & Foster, 1984). The shortened 20-item version used in this
study has been shown to correlate highly (r = .96) with scores from the longer version
(Robin & Foster, 1989). Assessment of the internal consistency for this new measure
revealed a coefficient alpha of .85 for parents and .88 for children.
Demographic Information
A demographic survey was given to participating parents to gain information
regarding number of parents involved in treatment or living in the home, patient’s
age, marital history of the parents, gender of the child, and duration of diagnosis (See
Appendix J).
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CHAPTER 4

RESULTS

Test-Retest Reliability
Test-Retest Reliability for Previously Established Measures
Test - retest reliability for the DFRQ, CFFRQ, SCI, Conflict Subscale –
DRCS, CBQ - parent, and the CBQ - child are presented in Table 5. Test reliability
was assessed by administering all measures a second time approximately two months
following the first administration. Tests were administered to patients who returned
to the clinic for follow-up appointments and were willing to complete the measure a
second time. The average amount of time between test administrations was 87 days
for the IDDM group (range = 29 days - 94 days) and 65 days for the CF group (range
= 17 days - 77 days). Cicchetti’s interpretive guidelines were used to rate the testretest reliability of the instruments on a scale from poor to excellent (poor = < .40,
fair = .40-.59, good = .60-.74, and excellent = .75 – 1.00). For the DFRQ, Pearson r
test-retest reliability was .83 for parents and .81 for children (N = 8), placing the
reliability of the DFRQ in the excellent category for both parents and children.
CFFRQ Pearson’s r test-retest reliability was .80 for parents and .85 for children (N =
6), again placing both parent and child reliability in the excellent range for the
CFFRQ. For the SCI, Pearson r test-retest reliability was .51 for parents and .81 for
children (N = 8), suggesting that the parents reliability was fair and child reliability
was excellent. The Conflict Subscale – DRCS revealed fair reliability for parents and
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good reliability for children with a Pearson r test-retest reliability of .59 for parents
and .65 for children (N = 8).

Table 5
Test-Retest Reliability Coefficients of the Previously Established Measures

Measure

N

Test-Retest

Internal Consistency

Parent

Child

Parent

Child

DFFRQ

8

.83

.81

.87

.83

CFRCS

6

.80

.85

.80

.74

SCI

8

.51

.81

.80

.48

Conflict Subscale – DRCS

8

.59

.65

.89

.95

CBQ

14

.39

.80

.85

.88

DFRQ = Diabetes Family Responsibility Questionnaire
CFFRQ = Cystic Fibrosis Family Responsibility Questionnaire
SCI = Self-Care Inventory
DRCS = Diabetes Responsibility and Conflict Scale
CBQ = Conflict Behavior Questionnaire

Pearson r test-retest reliability for the CBQ was .39 for parents and .80 for
children (N = 14), placing the reliability in the poor range for parents and the
excellent range for children. The discrepancy between parent and child test retest
reliability is not entirely unexpected and might be explained by the nature of conflict
and the measuring device itself (CBQ). This instrument is designed to detect the
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levels of conflict over a two week period, and the possibility of levels of conflict
being variable during the extended time between test-retest periods leaves open the
possibility that various conflict events might have occurred that changed reports on
this measure. Results suggest that parents might be more sensitive to the conflict
events that possibly occur during any given two week period and may be more likely
to report these events, thus reducing the reliability of a test-retest instrument such as
the CBQ when test-retest is conducted over an extended period of time like the 2-3
month period that elapsed between test-retest administrations in this investigation.
Test-Retest Reliability for Newly Developed Measures
Retest reliability for the newly developed SCI - CF and the Conflict Subscale
- CFRCS are presented in Table 6.

For the SCI - CF, Pearson’s r test-retest

reliability was .95 for parents and .32 for children (N = 6), suggesting that the parents

Table 6
Test-Retest Reliability Coefficients of the Newly Developed Measures

Measure

Test-Retest

N

Internal
Consistency

Parent

Child

Parent

Child

SCI – CF

6

.95

.32

.91

.84

Conflict Subscale - CFRCS

6

.71

.52

.82

.79

SCI – CF = Self-Care Inventory
CFRCS = Cystic Fibrosis Responsibility and Conflict Scale
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reliability was excellent and child reliability was poor. The Conflict Subscale –
CFRCS revealed Pearson’s r test-retest reliability was .71 for parents and .52 for
children (N = 6), placing the reliability of the Conflict Subscale – CFRCS in the good
category for parents and the fair category for children.

Convergent Validity Analysis
In IDDM research and clinical practice, Glycohemoglobin levels are often
used to measure the patient’s levels of adherence to the treatment regimen (Drotar &
Ivers, 1994; Miller & Drotar, 2003; Wiebe et al., 2005). In order to assess the
appropriateness of the SCI – CF as a measure of adherence in the CF group, levels of
Glycohemoglobin were correlated with the parent and child report of adherence (SCI)
using Pearson’s r to determine the association between Glycohemoglobin and SCI
scores for children with IDDM. In the 64 participants with IDDM, parent report of
adherence on the SCI correlated significantly negatively with treatment adherence
measured through Glycohemoglobin levels, r = -.56, p = < .01. In addition, child
report of adherence on the SCI correlated significantly negatively with levels of
Glycohemoglobin, r = -.39, p = < .01. This pattern of results suggested that parent
report on the SCI correlated adequately with physiological measure of adherence
(Glycohemoglobin levels) in the IDDM group.
No similar physiological measure of adherence was available for the SCI-CF
measure.

The SCI - CF, therefore, was used as the measure of adherence for

participants in the CF group while Glycohemoglobin levels were used to assess
adherence in the IDDM group (see Table 7).
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Correlation Analyses
Glycohemoglobin and Reported Adherence
To demonstrate that the SCI was an adequate measure of adherence, SCI
scores were correlated with Glycohemoglobin levels for participants in the IDDM
group. In the 52 participants with IDDM, parent report of adherence on the SCI
correlated significantly negatively with treatment adherence measured through
Glycohemoglobin levels, r = -.56, p = < .01 (see Table 7). These results suggest that
higher levels of adherence reported by parents on the SCI are significantly associated
with higher levels of adherence measured using Glycohemoglobin levels. As noted
earlier, lower levels of Glycohemoglobin indicate higher levels of treatment
adherence, therefore this negative correlation indicates parents are correlated with
accurate reporting regarding treatment adherence. Child report of adherence on the
SCI also correlated significantly negatively with levels of Glycohemoglobin, r = -.39,
p = < .01.
Adherence and Parent-Child Agreement Regarding Treatment Responsibility
For the 64 IDDM participant dyads, the exact agreement (calculated using the
number of agreements divided by the number of agreements plus disagreements and
multiplying by 100%) between parent and child perception regarding treatment
responsibilities correlated significantly in a negative direction with adherence
(Glycohemoglobin levels) in the IDDM group (r = -.30, p < .05). That is, higher
levels of exact agreement between parents and their child on task responsibility were
associated with lower levels of Glycohemoglobin; indicating higher levels of
adherence (see Table 7).
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Table 7
IDDM Correlations
Variable

1

1. Age

-

2. Duration
of illness

.30**

-

.17

.15

-

-.18

-.10

.35**

-

5. Overall family
conflict, parent
report (CBQ)

.06

-.05

.33**

.16

-

6. Overall family
conflict, child report
(CBQ)

.31*

-.03

.25*

.21

.39**

-

7. Parent Involvement,
parent report
(DFRQ)

.69**

.20

-.10

-.16

-.13

.10

-

.63**

.25*

-.04

-.21

-.06

-.05

.68**

3. Diabetes related
conflict, parent
report

36

4. Diabetes related
conflict, child report

8. Parent Involvement,
child report (DFRQ)

2

3

4

5

36

6

7

8

-

9

10

11

Table 7 – Continued
Variable

1

2

3

4

5

6

7

8

9

.00

.06

-.18

-.26*

-.01

.04

.08

.16

-

10. Adherence, parent
report (SCI)

-.35**

-.21

-.55**

-.27*

-.30*

-.24

-.14

-.24

.13

-

11. Adherence, child
report (SCI)

-.20

-.15

-.41**

-.25*

-.33**

-.21

-.12

.09

.23

.51**

-

12. Glycohemoglobin

.23

.31*

.43**

.27*

.12

.23

.00

-.01

-.30*

-.56**

-.39**

9. Parent and child
agreement of
perceived
responsibility

37

CBQ = Conflict Behavior Questionnaire
DRCS = Diabetes Responsibility and Conflict Scale
SCI = Self-Care Inventory
** p < .01
* p < .05
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10

11

For the 27 CF participant dyads, the exact agreement between parent and child
perception of treatment responsibilities correlated significantly with adherence
measured through parent report on the SCI, r = .47, p < .05.

Child report of

adherence on the SCI also correlated significantly with exact agreement between
parents and their children’s perceptions of who is responsible for treatment adherence
r = .42, p < .05. That is, parent and child report of higher levels of adherence for the
CF group was associated with greater levels of agreement between parent and child
regarding treatment responsibilities (see Table 8).
Adherence and Perceived Parental Involvement
The level of perceived parental involvement was assessed using the DFRQ
and the CFFRQ. On both of these measures parents and children were asked about
their perceptions about the person primarily responsible for treatment adherence.
Lower scores indicate perceptions associated with higher levels of parental
involvement in the treatment regimen. According to this measure, parent and child
report of level of parental involvement was not significantly correlated with
adherence (Glycohemoglobin levels) in the IDDM group (parents r = .00, p = .99;
children r = -.01, p = .96) (see Table 7). These results suggested that parent and child
report of perceived parental involvement in treatment were not associated with levels
of treatment adherence.
For the 27 CF participant dyads, parent and child report of level of parent
involvement were also not associated with levels of treatment adherence (SCI – CF
parent) (parents r = .23, p = .26; children r = .20, p = .31). Results of this analysis
suggest that parent and child report of parental involvement in completing treatment
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Table 8
CF Correlations
Variable

1

1. Age

-

2. Duration
of illness

.05

-

3. CF related conflict,
parent report

.25

.00

-

4. CF related conflict,
child report

.00

.15

.60**

-

5. Overall family
conflict, parent
report (CBQ)

.36

-.32

.37

.35

-

6. Overall family
conflict, child
report (CBQ)

.32

.00

.10

.25

.49*

-

.28

-.9

-.16

-.36

-.15

-.12

-

.09

.37

.28

-.11

-.37

-.34

.56*

-

-.16

.34

-.44*

-.28

-.41*

-.05

.35

.05

-

10. Adherence parent
report (SCI - CF)

-.24

.13

-32

-.08

-.37

-.14

.23

.06

.47*

-

11. Adherence, child
report (SCI - CF)

-.48*

-.06

-.09

-.03

-.25

-.32

.21

.09

.42*

.57**

7. Parental
involvement,
parent report
(CFRCS)
8. Parental
involvement, child
report (CFRCS)
9. Parent and child
agreement of
perceived
responsibility

2

3

4

CBQ = Conflict Behavior Questionnaire
CFRCS = Diabetes Family Responsibility Questionnaire
SCI - CF = Self-Care Inventory – Cystic Fibrosis
** p < .01
* p < .05
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5

6

7

8

9

10

components was not associated with levels of treatment adherence in either the IDDM
or CF groups (see Tables 7 and 8).
Adherence and Disease Related Conflict
Levels of conflict related to the IDDM treatment reported by parents on the
Conflict Subscale – DRCS correlated significantly in a positive direction with
adherence (levels of Glycohemoglobin), r = .43, p < .01. These results suggest that
parent report of higher levels of conflict surrounding the IDDM treatment
components are associated with lower levels of IDDM treatment adherence (see
Table 7). Conflict regarding IDDM treatment according to child report was also
significantly correlated with levels of adherence (r = .27, p < .05).
For the 27 CF participant dyads, neither parent nor child report of CF related
conflict correlated with levels of treatment adherence (SCI – CF parent) (parents r = .32, p = .12; children r = .08, p = .69). That is, parent and child report of CF related
conflict were not associated with levels of treatment adherence according to data
collected in this investigation (see Table 8).
Overall, levels of disease related conflict were not related to levels of
adherence in the CF and IDDM groups. The exception was in the IDDM group,
where parent report of diabetes related conflict was associated with lower levels of
treatment adherence, but child report was not. In the CF group, neither parent nor
child report of CF related conflict was associated with treatment adherence levels.
Adherence and Age
Age was not correlated with adherence as measured by levels of
Glycohemoglobin in the IDDM group (r = .23, p = .07). Based on the fact that lower
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levels of Glycohemoglobin indicate higher levels of treatment, these results suggest
that within the ages of 7-18, increased age is associated with lower levels of
adherence in the IDDM group (see Table 7).
For the 27 CF participant dyads, age was not significantly correlated with
levels of treatment adherence (SCI – CF parent), r = -.24, p = .24. It should be noted,
however, that child report of treatment adherence (SCI – CF child) correlated
significantly negatively with age, r = -.48, p < .01. These results suggest increased
child age is associated with significantly lower levels of treatment adherence in the
CF group (see Table 8). These results, however, should be interpreted with caution as
child report of adherence was not demonstrated to be a valid measure of adherence
within this investigation.
The analyses investigating the relationship between adherence and age
suggest that age was not significantly correlated with levels of treatment adherence
(Glycohemoglobin levels) in the IDDM group. In the CF group, however, older
children were also associated with lower levels of treatment adherence according to
child report (SCI – CF child). These results should be interpreted with some level of
caution because child report has demonstrated to be less accurate than parent report
throughout this investigation.

Between and Within IDDM and CF Group Differences
IDDM Within Group Differences
Paired-sample t-tests were conducted to assess potential differences between
parent and child report on the SCI, the DRCS, the Conflict Subscale – DRCS, and the
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CBQ within the IDDM group.

This analysis revealed a statistically significant

difference between the mean parent and child report of parental involvement in the
IDDM group measured on the DFRQ, t(64) = 6.00, p < .01 (see Table 9). These
results suggest that parents report a significantly greater level of parent involvement
in treating their child’s diabetes than do their children.

Difference were not

significant on the SCI, the Conflict Subscale – DRCS, and the CBQ in the IDDM
group, suggesting that any difference between parent and child report on these
measures were likely due to measurement error. Data collected in this study suggest

Table 9
Within Group Comparisons for IDDM Group

Measure

SD

Mean

t-test

p value

Parent

Child

Parent

Child

SCI

3.59

3.60

.63

.73

.14

p = .89

DFRQ

1.94

2.12

.29

.34

6.00

p < .01**

Conflict Subscale
– DRCS

11.27

13.56

8.70

13.23

1.41

p = .16

CBQ

7.25

6.96

3.89

4.00

.51

p = .61

SCI = Self-Care Inventory
DFRQ = Diabetes Family Responsibility Questionnaire
DRCS = Diabetes Responsibility and Conflict Scale
CBQ = Conflict Behavior Questionnaire
**p < .01
*p < .05
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that there are few significant differences between parent and child report within the
there IDDM group, other than parents reporting they are more involved in treatment
than their children.
CF Within Group Differences
To assess the differences between parent and child report in the CF group on
the modified SCI – CF, the CFRCS, the Conflict Subscale – CFFCS, and the CBQ,
paired-sample t-tests were also conducted (see Table 10). In the CF group, parents

Table 10
Within Group Comparisons for CF Group

Measure

SD

Mean

Parent

Child

SCI - CF

3.81

CFFRQ

t-test p value

Parent

Child

3.89

.59

.61

1.61

p = .12

29.37

33.00

5.23

5.27

4.47

p < .01**

Conflict Subscale
– CFRCS

9.22

19.26

7.43

19.09

3.30

p < .01**

CBQ

7.14

8.00

3.11

2.48

1.65

p = .11

SCI - CF = Self-Care Inventory - Cystic Fibrosis
CFFRQ = Cystic Fibrosis Family Responsibility Questionnaire
CFRCS = Cystic Fibrosis Responsibility and Conflict Scale
CBQ = Conflict Behavior Questionnaire
**p < .01
*p < .05
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reported a significantly lower level of treatment adherence than did their children
according to responses on the SCI – CF, t(27) = 3.36, p < .01. Results of these
analyses also suggested that parents reported that they were significantly more
involved in completing treatment components than their children reported on the
CFFRQ, t(27) = 3.36, p < .01. Children in the CF group reported a significantly
higher level of disease related conflict than did parents according to responses on the
Conflict Subscale – CFRCS, t(27) = 3.30, p < .01. Within the CF group, there were
no significant differences between parent and child report of overall level of conflict
as measured by the CBQ. On average, these results suggest that there were several
significant differences between parent and child report within the CF group. Parents
reported higher levels of involvement in treatment, lower levels of adherence, and
disease related conflict than their children.
Between IDDM and CF Group Differences
Independent-sample t-tests were conducted to determine differences between
the IDDM and CF groups (see Table 11). For these analyses parent and child mean
responses from the IDDM and CF participants were compared on the SCI & the
modified SCI – CF, the DFRQ & the CFFRQ, the Conflict Subscale – DRCS &
CFRCS, and the CBQ. In addition an independent-sample t-test was conducted to
determine if there was a significant difference between the level of agreement
between parent and children in the IDDM group versus the CF group regarding
treatment adherence responsibilities. This analysis was conducted by comparing the
mean level of agreement between parents and children in the IDDM group and the CF
group. T-test results suggested that children in the CF group reported higher levels
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Table 11
Between IDDM and CF Group Comparisons

Measure

Mean

IDDM

SD

CF

IDDM

CF

t-test

p value

SCI - Parent

3.60

3.81

.63

.59

1.51

p = .14

SCI – Child

3.60

4.02

.73

.55

2.93

p < .05*

FRQ - Parent

1.94

1.70

.29

.30

3.61

p < .01**

FRQ - Child

2.12

1.87

.34

.26

3.77

p < .01**

Conflict Subscale
RCS - Parent

11.27

9.22

8.70

7.43

1.13

p = .26

Conflict Subscale
RCS - Child

13.56

19.26

13.23

19.08

1.41

p = .16

CBQ - Parent

7.25

7.15

3.89

3.11

.13

p = .89

CBQ - Child

7.00

8.00

4.03

2.48

1.71

p = .14

Parent - Child
Agreement on
the FRQ

14.17

10.78

3.08

3.06

4.83

p < .01**

SCI = Self-Care Inventory
FRQ = Family Responsibility Questionnaire
RCS = Responsibility and Conflict Scale
CBQ = Conflict Behavior Questionnaire
**p < .01
*p< .05
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of treatment adherence than did children in the IDDM group, t(91) = 2.93, p < .05.
Furthermore, these analyses suggested that both parent and children reported a higher
level of parental involvement in treatment within the CF group compared to the
IDDM group, parents t(91) = 3.61, p < .01; children t(91) = 3.77, p < .01. Lastly,
IDDM parent and child dyads had a significantly higher level of agreement regarding
treatment responsibilities than did parents and children in the CF group, t(91) = 4.83,
p < .01.

ANOVA Analysis
Relationship between Parent and Child Agreement Regarding Treatment and Age
One-way ANOVAs were conducted to determine if there was a significant
difference in the levels of agreement between parents and their children regarding
treatment adherence responsibilities at different ages in both the IDDM and CF
groups. Visual inspection of the mean level of agreement for each age in the IDDM
group suggested that there was a drop between parent and child levels of agreement
from the ages eleven to fifteen (see Figure 1). An ANOVA with a Fisher’s Least
Significant Difference test (LSD) correction for multiple comparisons was conducted
to determine if there were significant differences between the mean parent and child
treatment agreement at different ages in the IDDM group.

Based on visual

inspection, three IDDM groups were developed for comparison; consisting of ages:
(a) eight through ten (N = 6) (young), (b) 11 through 15 (N = 30) (adolescent), and (c)
16 through 18 (N = 16) (older adolescent). The one-way ANOVA revealed no main
effects between these age groups regarding treatment adherence agreement in the
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Figure 1
Average Percent Agreement between Parents and their Children Regarding
Treatment Responsibilities by Age of Child (IDDM Group)
80%
75%

Mean Percent Agreement
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IDDM group. A curvilinear correction was also conducted for this analysis, and
again no main effects were found between age groups and level of parent and child
agreement regarding treatment adherence in the IDDM group.
For the CF group, visual inspection suggested variable patterns of agreement
between parent and child across ages, therefore an ANOVA was not conducted on
this group due to lack of justification for developing age groups due to variable levels
of agreement across ages (see Figure 2).
These results suggest the visually apparent curvilinear relationship between
children and parents agreement regarding diabetes treatment responsibilities and age
was not statistically significant. Furthermore, visual inspection revealed no patterns
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Figure 2
Average Percent Agreement between Parents and their Children Regarding
Treatment Responsibilities by Age of Child (CF Group)
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worthy of statistical analysis when agreement and age were evaluated for the CF
group. Parent and child responses in this data set, therefore, do not suggest that
discrepancies between parent and children regarding treatment responsibilities begin
at any particular age.
Relationship between Level of Parental Involvement and Age
A one-way ANOVA with an LSD correction for multiple comparisons was
conducted for both parent and child report of parental involvement in the CF and
IDDM groups. Results of the four one-way ANOVAs conducted between age and
level of parent involvement can be observed in Table 12. According to the report of
children within the IDDM group there was a significantly lower level of parent
involvement as they get older F(2, 62) = 23.00, p < .01. Parents in the IDDM group,
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Table 12
Parent and Child Reported Mean Scores of Parental Involvement in Treatment by
Age Group and Disease

Responder

Mean

F

p value

Younger

Adolescent

(ages 8-10)

(ages 11-15)

IDDM

1.57a

1.92b

2.16c

23.00 p < .01**

CF

1.53a

1.63a

1.91b

3.21

IDDM

1.61a

2.16b

2.31c

23.95 p < .01**

CF

1.80a

1.84a

1.94a

.37

Older
Adolescent
(ages 16-18)

Parent Report

p < .05*

Child Report

p = .69

Within any row, means with different subscripts differ significantly from each other according to
Fisher’s Least Significant Differences test.
**p < .01
*p < .05

also reported that their level of involvement significantly decreased as their child
grew older, F(2, 62) = 23.95, p < .01. Children in the CF group reported lower levels
of parental involvement only when comparing the younger & adolescent groups to the
older adolescent group (F(2, 62) = 3.21, p < .05) and parents of children with CF
reported no significant difference in their level of involvement as their children aged.
To further assess the potential difference in the IDDM and CF groups
regarding the level of parental involvement at different ages a 2 x 3 (disease x age)
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factorial analysis of variance was conducted. For this analysis, age groups (young 810, adolescent 11-15, and older adolescent 16-18) were identical to those used in the
one-way ANOVA investigating the relationship between age and level of parent and
child agreement. The purpose of this analysis was to determine if there was a
significant difference between the IDDM and CF groups in regard to the level of
parental involvement in treatment as children grow older.
According to parent report, there was a significant difference between age
groups (F(2, 89) = 13.79, p < .01) and between diseases (F(2, 89) = 8.61, p < .01),
however there was no significant interaction between parental involvement, age
group and disease when all were taken into account. These results can be observed in
Figure 3 where higher levels of responding indicate lower levels of perceived parental
involvement. Child report, however, revealed a interaction effect between age group
(F(2, 89) = 7.19, p < .01), disease group (F(1, 90) = 4.01, p < .01), and the
combination of age group and disease group (F(2, 89) = 4.75, p < .01). These results
suggest that, according to child report, there is a significant interaction effect between
the IDDM group and the CF group in regards to the level of parental involvement and
how it changes over time. In the CF group parent involvement appears to remain
high and stable as age increases, where in the IDDM group, parents appear to
gradually remove themselves from treatment responsibilities as their child grows
older. These results can be observed in Figure 4, and it should again be noted that
higher levels of responding are associated with lower levels of perceived parental
involvement.
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Figure 3
Level of Parental Involvement According to Parent Report by Age Group and
Disease
2.5

Level of Parental Involvement

2

IDDM Group

1.5

CF Group

1

0.5

0
Young 1(ages 8-10)

Adolescent2 (ages 11-15)

Older Adolescent
3 (ages 16-18)

Age Group

Note: Scores for parental involvement come from the DFRQ for participants with diabetes and the
CFFRQS for participants with CF. Higher scores indicate lower levels of parental involvement.

Regression Analysis
Approach to Regression Analysis
Regression analyses were completed to determine those variables that best
predicted levels of adherence and the relationship between agreement in parent and
child perceptions of responsibility, level of parental involvement, level of conflict and
age. All comparisons were plotted for visual inspection to determine if adjustments
were needed to accommodate curvilinear relationships between any of the variables.
Visual inspection suggested no curvilinear relationship between variables; therefore,
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Figure 4
Level of Parental Involvement According to Child Report by Age Group and
Disease
2.5

Level of Parental Involvement
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1.5
IDDM Group
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0
Young (8-10)

Adolescent (11-15)

Older Adolescent (16-18)

Age Group

Note: Scores for parental involvement come from the DFRQ for participants with diabetes and the
CFFRQ for participants with CF. Higher scores indicate lower levels of parental involvement.

linear regression analyses were conducted for both the IDDM and CF groups.
Regression Analysis Predicting IDDM Treatment Adherence
As a first step in the regression analysis for the IDDM group, all potential
predictor variables were correlated with the child’s Glycohemoglobin levels. Those
variables that were significantly correlated with Glycohemoglobin levels were
retained for a separate multiple regression analyses (enter and remove criteria of p <
.05). The retained variables and their correlations with Glycohemoglobin levels
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were: (a) parent report of diabetes related conflict (r = .43, p < .01), and (b)
agreement between parent and child report of parental involvement (r = .30, p < .05).
The final regression model for levels of adherence to the IDDM treatment
regimen as measured by Glycohemoglobin levels included two variables (see Table
13), F (2, 62) = 9.42, p < .01, R2 = .24. This regression analysis implicates parent
report of diabetes related conflict and discrepancies between parent and child report
of perceived responsibility regarding treatment adherence as significant predictors of
treatment adherence (Glycohemoglobin levels) in children with IDDM. It appears
that when parents and children agree on who is responsible for completing the various
aspects of the treatment regimen that levels of adherence may be higher. Furthermore
it appears that lower levels of conflict surrounding the diabetes treatment regimen
may predict higher levels of treatment adherence, or better Glycohemoglobin levels.
Regression Analysis Predicting CF Treatment Adherence
As a first step in the regression analysis for the CF group, all potential
predictor variables were correlated with the child’s adherence measured through
parent report.

Those variables that were significantly correlated with adherence

(measured with the SCI - CF) were retained for a regression analyses (enter and
remove criteria of p < .05). Only agreement between parent and child report of
parental involvement (r = .47, p < .05) was significantly correlated with levels of
reported adherence by the parent.
The final regression model for levels of adherence to the CF treatment
regimen as measured by parent report of adherence on the SCI – CF included one
variable (see Table 14), F (1, 27) = 7.09, p < .01, R2 = .22. This regression analysis
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Table 13
Predictors for Glycohemoglobin (HbA1)

Predictors

Standardized coefficients

T

p value

3.43

.00**

-1.98

.05*

Beta

Parent report of diabetes related .39
conflict

Exact agreement between parent and
child report on Diabetes Family -.23
Responsibility Questionnaire
Note. R2 values for Glycohemoglobin .24.
**p < .01
*p < .05

suggests that discrepancies between parent and child report of perceived
responsibility regarding treatment adherence are a significant predictor of treatment
adherence (measured by parent report on the SCI - CF) in children with CF. In other
words, when parents and children agreed on perceived responsibility for aspects of
the CF treatment regimen, levels of adherence were higher.
Comparison of Regression Analysis Results in IDDM and CF Group
Within both the IDDM and CF groups it appears that agreement between
parents and children on their perceptions of responsibility regarding completion of
treatment components was a significant predictor of adherence. It is important to note
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Table 14
Predictors for Reported CF Adherence (SCI-CF)

Predictors

Standardized coefficients

T

p value

2.66

.01**

Beta

Reliability score between parent and .49
child report on Diabetes Family
Responsibility Questionnaire - CF
Note. R2 values for higher levels of reported adherence .22.
**p < .01
*p < .05

that treatment adherence was reported through different measures in the IDDM group
and the CF group.

As previously mentioned, in the IDDM group, treatment

adherence was measured through Glycohemoglobin levels and in the CF group
adherence was measured through parent report. In both groups, however, results
suggest that agreement on who is responsible for treatment adherence predicts
adherence more accurately than other variables evaluated in this study including level
of parent involvement in treatment, levels of general family conflict and age of the
child.
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CHAPTER 5

DISCUSSION

Overview of the Current Investigation
Adherence to medical regimens for children and adolescents with IDDM and
CF is an important clinical issue in pediatric primary care. Low levels of adherence
impact overall health for the patient and complicate clinical decision-making for the
heath care provider.

Poor adherence, though, is common with levels of non-

adherence estimated as high as 80-90% for individuals with chronic illness such as
IDDM and CF (Anderson,et al., 1997; Jacobson, et al., 1990; Lask, 1994). Previous
research suggests that several psychosocial variables may impact adherence to
medical regimens including agreement between parents and children regarding
treatment responsibilities, conflict, and level of parental involvement. The current
study examined the impact of several of these factors on adherence in children with
IDDM and CF to clarify their relationship to adherence and determine if they have
similar impact across diseases.

Agreement on Perceived Treatment Responsibility and Conflict
Two previous studies have investigated the relationship between parent - child
agreement on perceived level of responsibility and adherence in IDDM with mixed
results. Anderson et al. (1990) reported that low levels of treatment adherence for
IDDM were predicted when parents and children reported that they both perceived
56

the other as responsible for treatment tasks. In contrast to these results, Miller and
Drotar (2003) did not find a predictive relationship between parent and child
agreement regarding perceived treatment responsibilities and IDDM treatment
adherence. No prior studies have investigated the relationship between agreement
and CF treatment adherence. A central finding of the current investigation is that
agreement between parents and children on treatment responsibilities was a
significant predictor of treatment adherence for both the IDDM and CF groups.
Previous studies assessed agreement by comparing mean scores and total scores from
parent and child measures of perceived responsibility. The current investigation,
however, compared parent and child responses on each individual item of the
instrument with a calculation of exact agreement. Exact agreement is likely a more
sensitive measure of agreement than comparing parent and child total scores, which is
the method used in several of the previous investigations into agreement. The use of
exact agreement eliminates the potential situation where parent and child mean scores
might agree, but their item by item scores do not agree.
The results of this investigation suggest that in both the IDDM and CF groups,
levels of exact agreement predict levels of treatment adherence over other variables
such as overall family conflict, level of parental involvement and the age of the child.
These data suggest that if parents and children disagree regarding who is responsible
for treatment tasks, steps should be taken to clarify treatment roles as a potential
means of increasing levels of agreement and, hopefully, levels of treatment
adherence.
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The direction and nature of disagreements between parents and children
regarding treatment responsibilities was not evaluated in this study. Previous studies
have investigated the impact of agreement on treatment adherence by comparing
mean levels of Glycohemoglobin for groups of parents and children that agree versus
groups that do not agree on treatment responsibilities (Drotar & Ivers, 1994; Miller &
Drotar, 2003).

Investigations that used group means have been unsuccessful in

finding statistically significant relationships between agreement and levels of
treatment adherence. The fact that agreement was found to be a significant predictor
of adherence in this investigation brings two possible explanations to bear.
First, it is possible that the method of using exact agreement between dyads to
measure agreement is a more sensitive method than group mean comparison for
measuring levels of agreement between parents and children regarding treatment
responsibilities. That is, it is possible that the differences may have existed in the
previously mentioned data sets, but that the different method used for data analysis
did not allow them to discover this phenomenon. For example, Drotar and Miller
(2003) defined agreement as both parent and child providing a child autonomy score
that fell on the same side of the median split, a potentially insensitive measure of
agreement. The second possible explanation is that the previously mentioned sample
and their resulting data sets were in some way palpably different from the current data
set in which differences in agreement were found to predict levels of treatment
adherence.

Future investigations would need to conduct both methods of data

analysis to determine which explanation fully accounts for the differences found in
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this investigation versus the others that studied the relationships between adherence
and levels of agreement.
If future investigations demonstrate that the method of data analysis was
responsible for the different results obtained in this investigations versus previously
conducted studies in this area; it may suggest that the direction and nature of the
disagreements between parents and children may not be as critical as identifying the
mere presence of disagreements. This information may have clinical implications as
clinicians might simply attempt to identify families where parents and children did
not agree on treatment responsibilities, instead of attempting to identify who might be
more, or less, responsible for completing treatment procedures. In other words, it
may not be important to know in what direction parents and children disagree
regarding who might be responsible for the IDDM or CF treatment, the critical
variable may be that they disagree on any level.
Previous studies establish a clear relationship between levels of conflict and
treatment adherence in the IDDM population (Martin et al., 1998, Miller & Drotar,
2003; Miller-Johnson et al., 1994) but the relationship between conflict and treatment
adherence has not been well investigated within the CF literature.

This study

confirmed the relatively well-established relationship between conflict and treatment
adherence within the IDDM population. Interestingly, however, only parent report of
diabetes related conflict and overall levels of family conflict were related to reported
treatment adherence (both parent and child report) and levels of treatment adherence
measured through Glycohemoglobin levels. Child report of conflict, either IDDMspecific or overall family, were not related to levels of treatment adherence. For both
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IDDM related conflict and overall family conflict, higher levels of parent reported
conflict were associated with lower levels of treatment adherence.
For the CF group there did not appear to be a significant relationship between
levels conflict reported by parents or children and reported levels of treatment
adherence. It is interesting to note, however, that children in the CF group reported
significantly higher levels of disease related conflict than did parents in the CF group.
In fact, children in the CF group reported the highest levels of disease related conflict
in this investigation. These results are interesting because parents and children in the
CF group reported much lower levels of overall family conflict when compared to the
IDDM group. Though the overall levels of conflict were not significantly different
among parents or children when comparing the IDDM and CF groups, overall family
conflict was substantially higher in the IDDM group. In contrast, levels of disease
related conflict was similar when comparing parents in the IDDM and CF groups.
However, children in the CF group reported particularly high levels of disease related
conflict. It is possible that children and adolescents with CF are particularly sensitive
or susceptible to disease related conflict, though; the increased report of conflict does
not appear to have a direct bearing on adherence.

Future investigations should

examine the impact of disease-related conflict on overall psychosocial well-being of
patients with CF.
In summary, the results of this investigation confirm that there is a predictive
relationship between parent - child agreement regarding treatment responsibilities and
treatment adherence and that disease-related conflict within the IDDM population is
also associated with adherence. However, the relationship between adherence and
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conflict in the CF population remains unclear despite the fact that this group
experiences particularly high disease-related conflict. One might assume that there is
a relationship between agreement regarding treatment responsibilities and conflict
(i.e., parents and children who agree about responsibility would have less disease
related conflict). Within the CF group, there does appear to be a relationship between
parent reported levels of disease related conflict, overall family conflict, and levels of
agreement regarding treatment responsibilities with greater levels of parent reported
conflict associated with lower levels of agreement regarding perceived treatment
responsibilities.

However, there does not appear to be any notable relationship

between levels of conflict and agreement in the IDDM group. These results suggest
that, though agreement and conflict are related to treatment adherence, agreement is
not necessarily related to levels of conflict.
Though it is certainly desirable for families to exist and work towards
treatment in a harmonious manner, agreement on treatment responsibility may be
more important that conflict levels for clinicians who wish to increase levels of
treatment adherence.

The relationship between conflict and level of treatment

adherence is difficult to interpret based on the results of this study, as conflict appears
to be related to IDDM treatment adherence and does not appear to relate to CF
treatment adherence, but the relationship between agreement and treatment adherence
is clear.

As stated earlier, agreement predicts treatment adherence over general

family conflict and other variables investigated within this study, therefore future
investigations in this area may want to focus on agreement alone and assess the
impact of agreement on adherence before delving into issues related to conflict.
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Mediating Effects of Age
Another variable investigated in this study was the age of the child and the
mediating effects of age on other variables in both the IDDM and the CF groups. For
the IDDM group, data collected in this investigation support the findings in previous
studies that younger children have higher levels of treatment adherence (Davis et al.,
2001; Johnson et al., 1992; Ricker et al., 1998; Rubin et al., 1989). In the CF
literature, Giess et al. (1992) and Zindani, Streetman, Streetmen, and Nasr (2006)
suggest that older children engage in higher levels of treatment adherence while other
investigations suggest that older children have lower levels of treatment adherence
(Abbott, & Gee, 1998; Drotar & Ivers, 1994; Patterson, 1985). The results of this
investigation support the latter studies with older children with CF having lower
levels of treatment adherence according to their own report.
In the current investigation, analyses were conducted to determine if there was
a relationship between levels of parent and child agreement and age. In other words,
attempts were made to identify at what age children and parents begin to disagree
regarding treatment responsibilities. The results suggest that there is no statistically
significant difference between age and levels of agreement between parents and
children regarding treatment responsibilities in either the IDDM or the CF group.
Visual inspection, however, suggests that levels of agreement in the IDDM group
were lower for the ages of 11 through 15 than they are for ages 8 through 10 and ages
16 through 18.

For the CF group, there were no identifiable patterns between

agreement and age though the relatively small sample size compared to the IDDM
group leads to cautious interpretation of this finding.
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Some cautious conclusions might be drawn from visually inspecting both the
IDDM group and the CF group. First, the pattern of responding in the IDDM group
suggests that more discrepancies between parents and their children occur during the
ages that are associated with onset of puberty and the traditional age that disease
related treatment responsibilities are passed from the parent to the child. Data in this
study support previous research that suggest parents are significantly less involved in
IDDM treatment as children grow older (Drotar & Ivers, 1994; Wiebe et al., 2005),
and corroborate the limited literature that suggest parental involvement is not
necessarily related to levels of treatment adherence in children with IDDM (Dashiff,
Bartolucci, Wallander & Abdullatif, 2005).

In the IDDM group, parental

involvement in treatment tasks decreases significantly as children grow older and
treatment adherence deteriorates, however, visual inspection suggests that the level of
agreement between parent and children is lowest during the ages of 11-15. It appears,
therefore, that as parents withdraw from assisting in the completion of treatment tasks
in the IDDM group that there may be confusion between parents and children
regarding who is responsible for completing treatment tasks.
The transition of treatment responsibility during the ages of 11-15 appears to
be a critical period for the IDDM group, however similar results were not found in the
CF group. Within the CF group, there is no discernable pattern between age and
parent - child agreement on perceived responsibilities. Furthermore, both parent and
children report suggests that there is no significant difference in the level of parent
involvement as children age. The current study does not reveal why this difference
occurs across diseases but future studies should attempt to determine if these
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differences might be due to the specific characteristics of the diseases and treatment
regimen. For example, parents of children with CF may stay more involved in
treatment due to fear that poor adherence will reduce the length of their child’s likely
shortened life (Foster, Eiser, Oades, Sheldon, Tripp, Goldman, Rice, & Trott, 2000).
Alternatively, aspects of the CF treatment that require assistance from other
individuals (e.g., back pounding to break up mucus that gathers in the lungs) may
facilitate more consistent parental involvement, where treatment tasks for IDDM can
essentially be complete independently (Zindani, Streetman, Streetmen, & Nasr,
2006).

Clinical Implications and Future Research
As stated earlier, a central finding within the current investigation was that
agreement between parents and children on who was perceived responsible for
completing treatment tasks was the best predictor of treatment adherence. These
results suggest that treatment outcome studies, targeting agreement, might be
conducted to assess how manipulating levels of agreement might influence levels of
treatment adherence. In other words, researchers may want to conduct studies that
compare groups where physicians or other medical staff specifically assign treatment
responsibilities to parents and children (targeting children ages 11-15) to groups that
implement a traditional method of addressing adherence (i.e., control group). Levels
of adherence and agreement could be assessed prior to, and following, these clinical
instructions. A study of this nature would provide more conclusive data regarding the
relationship between levels of agreement and treatment adherence. Furthermore, an
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investigation of this nature would provide valuable information regarding treatment
recommendations for physicians who treat child with IDDM or CF.
There are several other techniques that might be employed to investigate the
relationship between agreement and treatment adherence. One method might be to
systematically begin transferring responsibilities from the parent to the child when the
child reaches the ages of 10 or 11. The transfer of responsibility might be controlled
or recommended by the physician or medical staff personnel who commonly discuss
treatment adherence issues with the parents and the child. The medical staff could
systematically train the child to complete one treatment component at a time and
monitor the child’s progress in mastering each specific treatment task. Data might be
collected on how often the child is completing their treatment responsibilities, and
only when a child demonstrated high levels of competence and consistent adherence
for each newly introduced task would they be given responsibility for another
treatment component. To conduct this type of research, it would likely be important
to train the child on each specific task and monitor their ability to technically
complete the task as well as their ability to adhere to the task on a daily basis.
Despite the fact that there are some limitations to what conclusions can be
drawn regarding the relationship between age and treatment adherence in both the
IDDM groups and the CF groups based on the results of this study, these results do
suggest that physicians and clinicians that work with IDDM and CF populations
should consider agreement when conducting an assessment and when encountering
treatment adherence issues.

Recently, Wysocki (2006) published treatment

recommendations for clinicians who work with IDDM children.
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These

recommendations include making proper referrals when treatment adherence
problems arise, and conducting behavioral interventions focused on the specific
problems that are hypothesized to be preventing higher levels of treatment adherence.
The results of the current investigation support this notion, and suggest that future
research should investigate behavioral interventions focused on eliminating ambiguity
regarding who is responsible for the completion of treatment components by
systemically managing the transition of disease related responsibility from the parent
to the child.
There are several limitations that may influence the interpretation of the
results in this investigation. One limitation within the current investigation revolves
around the finding that the CF group reported higher levels of treatment adherence
but lower levels of agreement when compared to the IDDM group. This finding is
interesting because it appears undermine the notion that agreement is predictive of
treatment adherence, a central finding with this investigation.

This seemingly

contradictory result may be the result of using parent and child recall to measure
treatment adherence in the CF group.

Report and recall methods have been

established as highly variable in regards to reliability and validity, therefore all of the
measures used in this investigation should be interpreted with some level of caution.
Future studies in this area may consider exploring alternative methods, other than
participant report, to measure factors such as parental involvement in treatment and
levels of conflict.
Another potential weakness of the current investigation included the fact that
different measures of adherence were used in the IDDM group versus the CF group.
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Reports of adherence within the CF group should be interpreted with a greater level
of caution than in the IDDM group because adherence was measured through parent
and child report for the CF group. In contrast, the levels of adherence in the IDDM
group were measured using a physiological measure of adherence (Glycohemoglobin
levels) that has been well established in the adherence literature as an acceptable
means of assessing adherence within the diabetes population. All of the results in the
IDDM group, especially those that relate directly to levels of adherence, can be
interpreted with more confidence than the CF group.
Information regarding the proportion of the child’s life spent diagnosed with
diabetes or CF may also have been useful information in this study. Future studies
should attempt gain more information regarding the age and length of time that
participants have been diagnosed with chronic disease. This type of information (i.e.,
age of onset data) might be useful in determining the extent to which familiarity with
the regimen might influence levels of adherence. This type of information might be
particularly useful when studying the diabetes population as the length of diagnosis
and levels of treatment adherence were variable when compared to the more stable
CF group.
A final potential limitation to the current investigation lies within the time that
elapsed between the first and second administrations of the measures for which testretest reliability was calculated. There are different lengths of time that can be
appropriate for test-retest reliability, and a two-month interval between testing is not
unreasonable for the measures used in this study according to literature on test-retest
reliability. The test-retest reliability in this investigation was taken as a sample of
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convenience because patients were not willing to take time off of work, and remove
their children from school, to make a return visit to the clinic in order to take surveys
that could take them about 5 – 10 minutes to complete. The test-retest reliability data
in the current investigation does, however, appear to still make a substantial
contribution to the literature regarding the reliability (and the validity of the SCI) of
the measures implemented in this investigation as there was essentially no reliability
information regarding most of these measures previous to this investigation.
In all, the current investigation provides several contributions to the current
literature on adherence with the IDDM and CF populations. First, this investigation
provides data that implicates agreement as the most potent predictor of treatment
adherence in both the IDDM and CF groups. Physicians and researchers should
consider investigations and protocols that target agreement between parents and
children regarding treatment responsibilities for future investigations and clinical
practice. A second main finding of this study is that levels of parental involvement in
the IDDM group decrease as children get older, and those parents of children with CF
appear to remain consistently involved in the daily treatment of their children as they
age.

Physicians should take these group differences into account when making

treatment recommendations to families treating IDDM versus CF, especially when
making recommendations regarding who should be responsible for specific aspects of
the treatment regimen.
The intricate relationship between the level of parental involvement, age,
agreement, and treatment adherence will require extensive investigation to unravel.
Information gathered in this investigation appears to enhance the body of adherence
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knowledge by providing direction for future research that could influence the
development of “best practice” guidelines for clinicians who treat IDDM and CF in
their clinical practice. Ultimately, the goal of this line of research is to develop
effective strategies that help children with IDDM and CF live healthy and fulfilling
lives, especially during the ages of 11-15 where levels of treatment adherence can be
lowest. These results suggest that research leading to this end may revolve around
levels of agreement between parents and children regarding completion of the daily
aspects of their particular disease regimen. Treatment outcome research in this area
appears to be the next logical step in unearthing information that may directly impact
adherence, and the lives, of individuals with IDDM and CF.
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Self-Care Inventory (SCI-IDDM)
Please rate each of the items according to HOW WELL YOU FOLLOWED YOUR
PRESCRIBED REGIMINE FOR DIABETES CARE in the past month. Use the
following scale:
1 = Never do it
2 = Sometimes follow recommendations; mostly not
3 = Follow recommendations about 50% of the time
4 = Usually do this as recommended; occasional lapses
5 = Always do this recommendation without fail
N/A = Cannot rate this item / Not applicable
In the past month, how well have you followed recommendations for:
1. Glucose testing
1
2
3
4
5
2. Glucose recording
1
2
3
4
5
3. Ketone testing
1
2
3
4
5
4. Administering correct insulin
Dose
1
2
3
4
5
5. Administrating insulin at right
Time
1
2
3
4
5
6. Adjusting insulin intake based on
blood glucose values
1
2
3
4
5
7. Eating the proper foods; sticking
to meal plan
1
2
3
4
5
8. Eating meals on time
1
2
3
4
5
9. Eating regular snacks
1
2
3
4
5
10. Carrying quick acting sugar to
treat reactions
1
2
3
4
5
11. Coming in for appointments
1
2
3
4
5
12. Wearing a medical alert ID
1
2
3
4
5
13. Exercising regularly
1
2
3
4
5
14. Exercising strenuously
1
2
3
4
5
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N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
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Modified Self-Care Inventory – CF (SCI - CF)
Please rate each of the items according to HOW WELL YOU FOLLOWED YOUR
PRESCRIBED REGIMINE FOR CYSTIC FIBROSIS CARE in the past month. Use
the following scale:
1 = Never do it
2 = Sometimes follow recommendations; mostly not
3 = Follow recommendations about 50% of the time
4 = Usually do this as recommended; occasional lapses
5 = Always do this recommendation without fail
N/A = Cannot rate this item / Not applicable
In the past month, how well have you followed recommendations for:
1. Taking enzymes
1
2
3
4
5
2. Taking vitamins
1
2
3
4
5
3. Administering aerosal treatment 1
2
3
4
5
4. Administrating postural
drainage treatment
1
2
3
4
5
5. Eating the proper foods; sticking to
meal plan
1
2
3
4
5
6. Checking for weight change
1
2
3
4
5
7. Checking for infection
1
2
3
4
5
8. Determining right dose of
antibiotics
1
2
3
4
5
9. Administering correct antibiotic
Dose
1
2
3
4
5
10. Administering antibiotics at
right time
1
2
3
4
5
11. Coming in for appointments
1
2
3
4
5
12. Wearing a medical alert ID
1
2
3
4
5
13. Exercising regularly
1
2
3
4
5
14. Exercising strenuously
1
2
3
4
5
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N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
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Cystic Fibrosis Family Responsibility Questionnaire (CFFRQ)
Below are different tasks or situations that relate to cystic fibrosis management in
your family. Please check the box by the statement that describes the way each task
or situation is handled in your family.
1 = Parent (s) take or initiate responsibility for this almost all of the time
2 = Parent (s) and child share responsibility for this about equally
3 = Child takes or initiates responsibility for this almost all of the time
0 = No one takes responsibility
_____ 1. Remembering day of clinic appointments
_____ 2. Telling teachers about cystic fibrosis
_____ 3. Taking enzymes
_____ 4. Taking antibiotics (right dose at correct time)
_____ 5. Taking vitamins
_____ 6. Telling relatives about cystic fibrosis
_____ 7. Noticing differences in health such as weight changes or signs of infection
_____ 8. Telling child’s friends about cystic fibrosis
_____ 9. Taking aresol treatment
_____ 10. Taking postural drainage treatment
_____ 11. Deciding what should be eaten at meals
_____ 12. Explaining absence from school to teachers
_____ 13. Giving information to the doctor about condition during clinic visits
_____ 14. Discussing decisions about treatment with the doctor
_____ 15. Deciding what time of day postural draining treatments should be done
_____ 16. Deciding what time of day to take antibiotics
_____ 17. Deciding whether antibiotics need to be taken for symptoms
_____ 18. Making appointments with doctor
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Diabetes Family Responsibility Questionnaire (DFRQ)
Below are different tasks or situations that relate to diabetes management in your
family. Please check the box by the statement that describes the way each task or
situation is handled in your family.
1 = Parent (s) take or initiate responsibility for this almost all of the time
2 = Parent (s) and child share responsibility for this about equally
3 = Child takes or initiates responsibility for this almost all of the time
0 = No one takes responsibility
_____ 1. Remembering day of clinic appointments
_____ 2. Telling teachers about diabetes
_____ 3. Remembering to take morning or evening injections
_____ 4. Making appointments with doctors, dentists, etc.
_____ 5. Telling relatives about diabetes
_____ 6. Taking more or less insulin according to results of blood sugar or urine tests
_____ 7. Noticing differences in health, such as weight changes or signs of an
infection
_____ 8. Telling child’s friends about diabetes
_____ 9. Noticing the signs of an insulin reaction
_____ 10. Giving insulin injections
_____ 11. Deciding what should be eaten when family has meals out (restaurants,
friend’s home)
_____ 12. Examining feet and making sure shoes fit properly
_____ 13. Carrying some form of sugar in case of insulin reaction
_____ 14. Explaining absence from school to teachers or other school professional
_____ 15. Rotating injection sights
_____ 16. Checking expiration dates on medical supplies
_____ 17. Remembering times when blood or urine should tested
_____ 18. Having necessary supplies in the house
_____ 19. Adjusting insulin dose when the child is sick or has symptoms
_____ 20. Contacting doctor when the child is sick or has symptoms
_____ 21. Drawing up insulin
_____ 22. Doing blood sugar or urine tests
_____ 23. Keeping record of the tests
_____ 24. Deciding what should be eaten for snacks at home
_____ 25. Deciding what should be eaten for meals at home
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(Conflict Subscale - DRCS - Child)
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Conflict Subscale of the Diabetes Responsibility and Conflict Scale
(Conflict Subscale - DRCS - Child)
For each of the following parts of your diabetes care, decide how much you
argue/hassle with your parents about it.

1. Remembering to give shots
2. Drawing up insulin
3. Blood Testing
4. Record Keeping
5. Urine Testing
6. Giving Shots
7. Meals & Snacks
8. Taking care of low blood
sugar
9. What to eat when eating away
from home
10. Talking with the doctor
11. Talking with other adults
about diabetes (like teacher,
nurse, principal)
12.
Telling friends about
diabetes
13. Exercising
14. Who should know about
your diabetes
15. Supplies

Never Sometimes

½ The Frequently All The
Time
Time























































































































































87

Appendix F
Conflict Subscale of the Diabetes Responsibility and Conflict Scale
(Conflict Subscale - DRCS - Parent)
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Conflict Subscale of the Diabetes Responsibility and Conflict Scale
(Conflict Subscale - DRCS - Parent)
For each of the following parts of your child’s diabetes care, decide how much you
argue/hassle with your child about it.
Never Sometimes ½ The Frequently All The
Time
Time
1. Remembering to give shots





2. Drawing up insulin





3. Blood Testing





4. Record Keeping





5. Urine Testing





6. Giving Shots





7. Meals & Snacks





8. Taking care of low blood 




sugar
9. What to eat when eating away 




from home
10. Talking with the doctor





11. Talking with other adults 




about diabetes (like teacher,
nurse, principal)
12.
Telling friends about 




diabetes
13. Exercising





14. Who should know about 




your child’s diabetes
15. Supplies
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Conflict Subscale of the Cystic Fibrosis Responsibility and Conflict Scale
(Conflict Subscale - CFRCS - Child)
For each of the following parts of your diabetes care, decide how much you
argue/hassle with your parents about it.

1. Antibiotics
2. Enzymes
3. Vitamins
4. Tracking weight
5. Checking for infection
6. Aerosal treatment
7. Meals & Snacks
8. Postural drainage treatment
9. What to eat when eating away
from home
10. Talking with the doctor
11. Talking with other adults
about cystic fibrosis (like
teacher, nurse, principal)
12. Telling friends about cystic
fibrosis
13. Exercising
14. Who should know about
your cystic fibrosis
15. Supplies

Never Sometimes

½ The Frequently All The
Time
Time
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Conflict Subscale of the Cystic Fibrosis Responsibility and Conflict Scale
(Conflict Subscale - CFRCS - Parent)
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Conflict Subscale of the Cystic Fibrosis Responsibility and Conflict Scale
(Conflict Subscale - CFRCS - Parent)
For each of the following parts of your child’s cystic fibrosis care, decide how much
you argue/hassle with your child about it.

1. Antibiotics
2. Enzymes
3. Vitamins
4. Tracking weight
5. Checking for infection
6. Aerosal treatment
7. Meals & Snacks
8. Postural drainage treatment
9. What to eat when eating away
from home
10. Talking with the doctor
11. Talking with other adults
about cystic fibrosis (like
teacher, nurse, principal)
12. Telling friends about cystic
fibrosis
13. Exercising
14. Who should know about
child’s cystic fibrosis
15. Supplies

Never Sometimes

½ The Frequently All The
Time
Time
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Conflict Behavior Questionnaire (CBQ)
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Conflict Behavior Questionnaire (CBQ)
Think back over the last 2 weeks at home. The statements below have to do with you
and your mother. Read the statement and then decide if you believe the statement is
true. If it is true, then circle true, and if you believe the statement is not true, circle
false. You must circle either true or false, but never both for the same item. Please
answer all items. Your answers will not be shown to your parents.
true
true
true
true
true
true
true
true
true
true
true
true
true

false
false
false
false
false
false
false
false
false
false
false
false
false

true
true
true
true
true
true
true

false
false
false
false
false
false
false

1. My mom doesn’t understand me.
2. My mom and I sometimes end our arguments calmly.
3. My mom understands me.
4. We almost never seem to agree.
5. I enjoy the talks we have.
6. At least three times a week, we get angry at each other.
7. My mother listens when I need someone to talk to.
8. My mom is a good friend of mine.
9. She says I have no consideration for her.
10. At east once a day we get angry at each other.
11. My mother is bossy when we talk.
12. The talks we have are frustrating.
13. My mother understands my point of view, even when she doesn’t
agree with me.
14. My mom seems to be always complaining about me.
15. In general, I don’t think we get along very well.
16. My mom screams a lot.
17. My mom puts me down.
18. If I run into problems, my mom helps me out.
19. I enjoy spending time with my mother.
20. When I state my opinion, she gets upset.
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Demographic Information
1) SEX OF CHILD (CHECK ONE): ___Male

___Female

2) AGE OF CHILD: ______
3) DURATION SINCE DIAGNOSIS (CHECK ONE):
___1 year ___2 years ___3 years ___4 years ___5 years ___6 years ___7 years or
more 4) MARITAL STATUS OF BIOLOGICAL PARENTS (CHECK ONE):
___Continuously Married
___History of Separation /Divorce
___One Parent Deceased
5) LIVING SITUATION OF CHILD (CHECK ONE):
___Lives with Mother and Father
___Lives with Mother
___Lives with Father
___Lives with Mother and Stepfather
___Lives with Father and Stepmother
___Other
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HSIRB Approval Letter
Date: November 11, 2004
To:

Linda LeBlanc, Principal Investigator
Blake Lancaster, Student Investigator for dissertation

From: Amy Naugle, Ph.D., Interim Chair
Re:

HSIRB Project Number: 04-07-06

This letter will serve as confirmation that your research project entitled “Examination
of the Impact of Age, Family Conflict, and Perceived Parental Involvement on
Treatment Adherence for Children and Adolescents with Cystic Fibrosis and
Diabetes” has been approved under the full category of review by the Human
Subjects Institutional Review Board. The conditions and duration of this approval are
specified in the Policies of Western Michigan University. You may now begin to
implement the research as described in the application.
Please note that you may only conduct this research exactly in the form it was
approved. You must seek specific board approval for any changes in this project.
You must also seek reapproval if the project extends beyond the termination date
noted below. In addition if there are any unanticipated adverse reactions or
unanticipated events associated with the conduct of this research, you should
immediately suspend the project and contact the Chair of the HSIRB for consultation.
The Board wishes you success in the pursuit of your research goals.

Approval Termination:

July 21, 2005
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